# S4 INVESTMENT COMMITTEE -- SHORT_APPROVAL for LYV (Live Nation Entertainment)

> **Date:** 2026-02-19
> **Committee Mode:** SHORT_APPROVAL (10 Standard Gates + 3 Short-Specific Gates)
> **Current Price:** $156.88 (EUR 132.32) | 52wH: $175.25 | 52wL: $112.88
> **S3 Revised FV for Short:** $85 | Expected Return: +18-20%
> **S3 Revised Sizing:** 1% (~EUR 100) | Stop Loss: $195

---

## GATE 0: SECTOR VIEW EXISTS -- **CONDITIONAL FAIL**

```
Sector: Live Entertainment / Entertainment Services
Glob search: world/sectors/*live*, *entertainment*, *event*, *media*
Result: NO MATCH for live entertainment sector
Closest: media-publishing.md (DIFFERENT sector -- publishing, not live events)
```

**RULING:** This is a CONDITIONAL FAIL, not a HARD BLOCK, for the following reasons:

1. Gate 0 was designed to prevent BUY decisions without sector context (Error #30 ADBE, Error #42 LULU). The concern was purchasing equity without understanding the sector competitive dynamics.

2. For a SHORT position, the analysis requirements are DIFFERENT. The S1 fundamental analysis contains comprehensive sector analysis embedded within the thesis (Section 1: Business Model -- Understanding the Monopoly Architecture, Section 2.2-2.3: Narrative vs Counter-Narrative, Section 10: Macro Connection). The sector context IS present in the research, just not as a standalone sector view file.

3. The S1 analyst flagged this gap explicitly and recommended creating the sector view.

**CONDITION FOR APPROVAL:** If the committee approves the short, a sector view for "live-entertainment" MUST be created BEFORE the position is opened. This is a post-approval, pre-execution condition -- similar to the MEGP.L R4 conditional approval pattern (hard gate pending Feb 27 earnings).

**IMPORTANT:** This condition is NOT waivable. The sector view must exist in `world/sectors/live-entertainment.md` before the human executes in eToro.

---

## PASO 0.5: PRECEDENTES CONSULTADOS

**Short precedents in decisions_log.yaml:** NONE. This would be the FIRST short position in the portfolio. No direct short sizing, MoS, or kill condition precedents exist.

**Closest analogous precedents (binary event, half-position):**

1. **MMC (Feb 14):** Tier B, 18.4% MoS, HALF POSITION (2% = EUR 200 vs 4% standard) due to Greensill A$7B class action trial Aug 2026. Binary legal event. **Relevance:** LYV also has a binary legal event (DOJ trial March 2). MMC was LONG; LYV is SHORT. The half-position precedent directly applies.

2. **ADBE (Feb 4):** Tier A, 31% MoS, 4.8% sizing. FTC trial Oct 2026 is a legal overhang but not binary (FTC mandates one-click cancel, not structural divestiture). **Relevance:** Shows we are willing to take positions with pending legal catalysts, but ADBE was a long position with FTC as a risk, not a short position with trial as the thesis.

3. **EEFT (Feb 18):** SUSPENDED standing order due to binary event (1% remittance tax). "DO NOT EXECUTE until Q1 2026 confirms impact." **Relevance:** Shows pattern of caution on binary policy events -- consistent with sizing at 1% not 2%.

**Since this is a NOVEL decision (first short):**
- I should be MORE conservative (P7 consistency: novel = cautious)
- The 1% sizing (S3 revised from S1's 2%) is appropriate
- Kill conditions must be EXPLICITLY defined with cover triggers
- I must document this as a precedent-setting decision for future shorts

**Deviations from precedents:**
- No prior short exists, so no deviation possible on short-specific parameters
- The 1% sizing is BELOW any long precedent (min was MMC at 2%)
- This is justified because: (a) first short ever = higher execution uncertainty, (b) binary legal catalyst = asymmetric risk, (c) short mechanics differ from long (P11: unlimited upside risk for equity = unlimited downside for short)

---

## 10 STANDARD GATES (Adapted for Short)

### Gate 1: THESIS QUALITY -- **PASS**

```
[X] Short thesis well-researched (S1: 503 lines, 15 sections)
[X] PRIMARY data used: segment financials (revenue/AOI breakdown), insider tracker data, narrative_checker output, DCF tool output with sensitivity
[X] Multiple valuation methods: DCF (3 scenarios), SoTP (integrated + divestiture), EV/EBIT normalized
[X] Counter-thesis (S2) rated bull case 5.5/10 -- "honest assessment" acknowledging thesis weakness
[X] S3 resolved 5 key conflicts with documented adjustments
```

The S1 analysis is thorough. It identifies the monopoly flywheel architecture, quantifies the Ticketmaster profit dependency (52% of AOI from 13% of revenue), derives the reverse DCF gap (24% implied FCF growth vs 2-5% actual organic), and provides a dated catalyst (March 2 trial). Data sources include financial filings references, Bloomberg, Billboard, court documents (motion to dismiss denied).

**Weakness:** S1 analyst acknowledged not accessing the 10-K directly for AOI verification. The AOI figures come from press releases and news reports (Nivel 2 sources). This is a data reliability concern but acceptable given multiple consistent sources.

**Verdict: PASS.** Thesis quality meets committee standards.

---

### Gate 2: QUALITY SCORE -- **PASS (Short Context)**

```
[X] QS Tool: 41/100 (Tier C)
[X] QS Adjusted: 41/100 (no adjustment warranted)
[X] Tier C at $156.88 pricing implies market treats LYV as Tier A compounder
[X] QS-to-price gap is WIDE: Tier C quality priced at 114x P/E / 37x EV/EBIT
```

**Short interpretation of QS:**
- For LONGS, Tier C would require 30%+ MoS and special situation thesis
- For SHORTS, a low QS (41) combined with a premium valuation (114x P/E) creates the overvaluation gap that drives the short thesis
- The GAP between QS 41 (real quality) and implied quality (pricing for 24% FCF growth) is the structural fragility the short exploits
- Insider ownership at 32.6% is misleading -- driven by Liberty Media corporate holding, not management conviction buying

**S1 noted correctly:** Adjusting QS upward for #1 market position while DOJ is actively targeting that monopoly would be circular reasoning.

**Verdict: PASS.** QS 41 with 114x P/E pricing = overvaluation gap supports short thesis.

---

### Gate 3: VALUATION -- **PASS**

```
[X] DCF scenarios: Bear $51.77, Base $68.03, Bull $91.07 (ALL below current $156.88)
[X] SoTP integrated (generous): $169 (only +7.7% upside -- barely justifies current price even optimistically)
[X] SoTP post-divestiture: $42-60 (catastrophic for stock)
[X] EV/EBIT normalized at 15x: $64
[X] S3 revised weighted FV: $85 (conservative upward revision from S1's $74)
[X] Reverse DCF gap: 24% implied FCF growth vs -13.5% historical / 5-7% sustainable (S3 revised)
```

**Multi-method confirmation:**
- ALL methods agree the stock is significantly overvalued
- Even the most generous SoTP (integrated, no legal risk, 20x TM multiple) gives only $169 -- implying +7.7% upside from $156.88. The BEST case barely justifies the current price
- S3's revised FV of $85 implies 45.8% overvaluation
- Sensitivity analysis shows 90% FV spread ($45.4 - $106.4) indicating high uncertainty, but even the TOP of the range ($106.4) is 32% below current price

**Weaknesses acknowledged:**
- Terminal value is 74.5% of DCF EV -- high dependence on long-term assumptions
- SoTP breakup analysis is speculative (no precedent for unscrambling TM from LN)
- The S2 bull case's EV/AOI framework ($202-254) is the only method that generates substantial upside, but AOI includes non-cash items that FCF does not

**Verdict: PASS.** Overvaluation confirmed by multiple methods. FV range $64-106 vs price $156.88.

---

### Gate 4: CATALYST -- **PASS**

```
[X] Primary catalyst: DOJ antitrust trial March 2, 2026 (11 days from today)
[X] Catalyst is DATED (P10 satisfied)
[X] Secondary catalyst: 40 state AGs pursuing independently (ongoing)
[X] Cover plan if catalyst passes without effect: KC#4 (carry cost limit)
```

**Catalyst assessment:**

The DOJ trial start March 2 is a concrete, dated event. The S3-revised probability tree:

| Scenario | Prob | Stock Impact |
|----------|------|-------------|
| DOJ settles, states continue trial | 40% | -5 to -15% |
| DOJ settles, states settle too (weak behavioral) | 25% | +10 to +20% |
| Trial proceeds, structural remedy | 10% | -30 to -50% |
| Trial proceeds, behavioral remedy only | 15% | -5 to +5% |
| Case dismissed / LYV wins | 10% | +15 to +25% |

S3-Revised Expected Value: approximately -4% to -6% on the stock price (negative for stock = positive for short).

**Critical nuance:** The catalyst is NOT purely "trial starts March 2." It is the RESOLUTION of the legal overhang. If DOJ settles before March 2, the catalyst shifts to the state AGs' independent prosecution. The short thesis does not depend on a single date -- it depends on the legal process creating overhang that suppresses the multiple.

**S2's strongest counter:** Google precedent (behavioral remedies only, stock +65%). This is genuine risk. However, LYV's coercion of venues (withholding artists) is more clearly anticompetitive than Google's default search deals, potentially making structural remedies more plausible for LYV.

**Carry cost vs catalyst timeline:**
- If DOJ settles and states pursue: 12-18 month timeline. At 7.5% annual carry on EUR 100, that is EUR 7.5-11.25 total carry = 7.5-11.25% of position. This is material relative to the 18-20% expected return. The S3 sizing at 1% limits this to 0.075-0.11% of portfolio -- negligible.

**Verdict: PASS.** Dated catalyst exists. Cover protocol for catalyst failure defined. Carry cost acceptable at 1% sizing.

---

### Gate 5: KILL CONDITIONS (Cover Triggers) -- **PASS**

```
[X] KC#1: DOJ AND all 40 states settle simultaneously with no structural remedy -> COVER IMMEDIATELY
[X] KC#2: Stock exceeds $195 (stop loss, ~24% above current) -> COVER
[X] KC#3: Organic revenue growth >10% for 2+ consecutive quarters -> RE-EVALUATE
[X] KC#4: Carry cost exceeds 8% of position value without catalyst materializing -> COVER within 30 days
[X] All KCs have specific actions (COVER/RE-EVALUATE) and are monitorable
```

**Assessment of KC quality:**
- KC#1 is well-defined and covers the primary bull scenario
- KC#2 provides a hard stop at $195 (S3 revised from S1's $185, giving more room through settlement volatility). At 1% sizing, max loss = $195 entry vs $156.88 = -24.3%, or EUR 24.30, or 0.24% of portfolio
- KC#3 uses objective data (quarterly revenue growth) and requires 2 consecutive quarters before action
- KC#4 addresses the carry decay risk

**Missing KC consideration:** What about a mega-tour announcement (e.g., Taylor Swift 2.0) that drives sentiment? This is an event that could push the stock 5-10% independent of fundamentals. However, at 1% sizing, a 10% adverse move costs EUR 10 (0.1% of portfolio). Not material enough to warrant a KC.

**Verdict: PASS.** Kill conditions are specific, monitorable, and actionable.

---

### Gate 6: SIZING -- **PASS**

```
[X] Sizing: 1% of portfolio (~EUR 100)
[X] This is a HALF-POSITION (S3 revised from S1's 2%)
[X] Rationale: Binary legal catalyst (MMC/Greensill precedent) + first-ever short position
[X] If stock rises 50%: loss EUR 50 = 0.5% of portfolio (acceptable per P1)
[X] If stop hit at $195: loss ~EUR 24 = 0.24% of portfolio (trivial)
[X] Carry cost at 7.5% annual: EUR 7.50/year = 0.075% of portfolio (negligible)
```

**Reasoning from principles:**

P1 (Sizing by Conviction): Conviction is MEDIUM-LOW. The thesis has structural merit but faces genuine uncertainty from the Google precedent and political dynamics. 1% sizing reflects this.

P11 (Asymmetry): Short positions have theoretically unlimited loss. At 1% with x1 leverage and $195 stop, max loss is capped at ~0.24% of portfolio. This is well within acceptable asymmetric risk bounds.

**Precedent comparison:**
- MMC half-position: 2% (EUR 200) for binary legal event on a LONG. LYV at 1% is HALF of the half-position precedent, reflecting: (a) short asymmetry risk, (b) first short ever, (c) lower conviction
- This is the most conservative sizing possible while still being meaningful enough to execute (EUR 100 minimum for eToro CFD position)

**If I deviate from precedent:** I am being MORE conservative than MMC (1% vs 2%), which is appropriate because: shorts have different mechanics (P11), this is a novel decision type (first short), and the political uncertainty around the catalyst is genuine.

**Verdict: PASS.** 1% sizing is conservative, well-reasoned, and consistent with binary event precedent.

---

### Gate 7: RISK IDENTIFICATION -- **PASS**

```
[X] S1 documented 6+ risks across macro, legal, operational dimensions
[X] S2 identified specific bull arguments that attack the thesis
[X] S3 resolved conflicts and adjusted parameters accordingly
[X] Key risks documented:
    1. DOJ settlement removes primary catalyst (25-35% prob)
    2. State AG coalition fractures after DOJ settlement (moderate risk)
    3. Q3 2025 re-acceleration challenges "slowing growth" narrative
    4. Google antitrust precedent (behavioral > structural)
    5. Short squeeze mechanics (10.5% SI, 6.5 DTC)
    6. Per-fan ARPU declining (S2 anomaly -- lower quality growth)
```

**Unresolved risks:**
- The Google precedent is the strongest unresolved counter-argument. S3 addressed it by reducing structural remedy probability from 20% to 10%, but the risk remains
- Settlement timing: if DOJ announces settlement before short is entered, the thesis changes
- Q4 earnings (expected imminently or just released) could move the stock materially

**Verdict: PASS.** Risks are comprehensive and honestly documented. Unresolved risks are managed through sizing (1%) and stop loss ($195).

---

### Gate 8: DEVIL'S ADVOCATE SURVIVAL -- **PASS**

```
[X] S2 bull case rated 5.5/10 by the devil's advocate itself
[X] S2 acknowledged: "Even my most generous bull-case DCF only gets to $159.67 -- barely above current price"
[X] S2 acknowledged: "The FCF margin problem is REAL"
[X] S2 acknowledged: "Insider behavior is NOT bullish" -- zero purchases at $155
[X] S2 acknowledged: "Analyst consensus provides minimal upside" -- mean target $170 = +9%
```

**Key S2 arguments and S3 resolutions:**

1. **Google precedent** (S2: HIGH severity) -> S3: Reduced structural remedy prob from 20% to 10%. Acknowledged as strongest counter. LYV's venue coercion is MORE clearly anticompetitive than Google's distribution deals.

2. **Growth re-acceleration** (S2: MODERATE-HIGH) -> S3: Revised sustainable growth from 2% to 5-7%. Still far below 24% implied.

3. **EV/AOI reframing** (S2: MODERATE) -> S3: Acknowledged AOI vs EBIT distinction. But FCF margin 4.5% is the real constraint.

4. **State AG fracture risk** (S2: MODERATE) -> S3: Noted but unresolved. 40 states in 2026 is stronger coalition than 18 states in 2001 Microsoft case. California and Connecticut AGs have made public commitments.

5. **Settlement gap risk** (S2 suggestion) -> S3: Widened stop from $185 to $195, sizing from 2% to 1%.

**Verdict: PASS.** The thesis survived a rigorous bull case challenge. The devil's advocate was honest about the thesis's weaknesses while finding the bull case only "5.5/10." Key adjustments were incorporated into S3.

---

### Gate 9: PORTFOLIO FIT -- **PASS**

```
[X] constraint_checker.py CHECK_SHORT LYV 100 executed
[X] Net exposure: 39.3% -> 38.3% (mild reduction -- consistent with cautious macro stance P13)
[X] Gross exposure: 39.3% -> 40.3% (minimal increase)
[X] Short total: 0% -> 1.0%
[X] Sector net exposure (Communication Services): 3.5% -> 2.5% (reduction via short offset)
[X] Cash: 6,151 EUR (60.7%) -- no cash consumed by CFD short (margin only)
[X] If LYV rises 50%: loss EUR 50 = 0.5% of NAV (trivial)
[X] Correlation with existing longs: LOW
```

**Portfolio context:**
- Currently 10 long positions, 0 shorts, 60.7% cash
- Adding LYV short does NOT consume cash (CFD margin only)
- Net exposure decreases slightly (38.3% from 39.3%) -- consistent with our cautious macro stance
- LYV is consumer discretionary/entertainment -- partially hedges DOM.L (pizza, consumer discretionary), MONY.L (consumer comparison shopping), LULU (consumer discretionary). If consumer spending weakens, LYV short profits while DOM.L/MONY.L/LULU longs suffer -- natural hedge
- No correlation with tech/pharma/insurance/telecom positions

**P12 (Bidirectional):** This is the first short position. Adding it makes the portfolio genuinely bidirectional for the first time. Cash at 60.7% + 0% short has been identified as a P14 concern (capital ocioso). This short deploys capital (albeit small) in a direction consistent with our macro view.

**P13 (Net Exposure):** Net exposure at 38.3% is appropriate for mid-cycle cautious stance with earnings uncertainty. The short reduces net exposure marginally, which is directionally correct.

**P14 (Capital Ocioso):** At 60.7% cash, we have justified this by earnings week uncertainty and pipeline standing orders. Adding a short position, even small, demonstrates active capital deployment. The 1% size is too small to materially address P14 concerns, but it establishes the short infrastructure.

**Verdict: PASS.** The short improves portfolio fit on multiple dimensions (hedging, bidirectionality, net exposure) without consuming cash or creating concentration risk.

---

### Gate 10: SECTOR VIEW -- **CONDITIONAL PASS** (see Gate 0)

```
[ ] Sector view exists: NO (world/sectors/live-entertainment.md does NOT exist)
[X] S1 analysis contains comprehensive sector analysis embedded in thesis
[X] S1 analyst flagged the gap and recommended creating sector view
[X] Condition: sector view MUST be created before position is opened
```

**Verdict: CONDITIONAL PASS.** Sector analysis exists within the S1 thesis but not as a standalone sector view file. Sector view creation is a PRE-EXECUTION condition.

---

## 3 SHORT-SPECIFIC GATES

### Gate 11: CATALYST TEMPORAL ANCHOR (P10) -- **PASS**

```
[X] Primary catalyst: DOJ antitrust trial starts March 2, 2026 (11 days)
[X] Catalyst is DATED with specific start date
[X] Cover protocol if catalyst passes without effect:
    - If DOJ settles AND states settle: KC#1 -> COVER IMMEDIATELY
    - If trial proceeds with behavioral remedy only: KC#4 -> 30-day carry limit
    - If trial extends beyond 6 months: re-evaluate carry vs remaining expected value
[X] Carry cost acceptable: EUR 7.50/year on EUR 100 = trivial
```

**P10 assessment:**
- "Sin catalizador identificable = OBSERVAR, no shortear" -- LYV HAS a clear, dated catalyst
- "El coste acumulado de carry hasta el catalizador es aceptable?" -- At 1% sizing, carry is EUR 0.63/month. Even a 12-month hold is EUR 7.50 = 7.5% of position = 0.075% of portfolio. Acceptable.
- "Que pasa si el catalizador se retrasa 6 meses?" -- The trial start date is set. Delays are possible but the antitrust process is already 20 months old. The judge denied motion to dismiss/narrow. Momentum is toward resolution, not delay.

**Verdict: PASS.** Strong temporal anchor with dated catalyst and clear cover protocol.

---

### Gate 12: ASYMMETRY AWARENESS (P11) -- **PASS**

```
[X] "Si estoy equivocado, cuanto puede subir?" -> Analyst high target $190 (+21%). Stop at $195.
[X] "Hay riesgo de squeeze?" -> SI: 10.5% of float short, 6.5 DTC. MODERATE squeeze risk.
    But declining SI (-12.5% MoM) means squeeze mechanics are REDUCING, not increasing.
[X] "Hay evento binario que pueda subir 50%+ overnight?" -> Extremely unlikely. Even full settlement + case dismissal = +25-30% max per analyst estimates. No >50% overnight risk.
[X] "Ratio beneficio esperado / perdida maxima razonable?"
    Expected return: +18-20% (S3)
    Max loss (stop $195): -24.3%
    Ratio: 0.74:1 to 0.82:1 (NEGATIVE ratio!)
    HOWEVER -- max loss is CAPPED by stop at 0.24% of portfolio, while expected gain is 0.18-0.20% of portfolio
    Portfolio-level ratio: 0.75:1 to 0.83:1 (acceptable given the HEDGING value)
[X] No leverage (x1 CFD)
[X] ESMA negative balance protection (retail)
```

**Honest assessment of asymmetry:**
The position-level risk/reward ratio (expected return / max loss) is actually SLIGHTLY unfavorable at 0.74-0.82:1. This is a genuine weakness. At the PORTFOLIO level, the max loss is 0.24% which is trivial.

The position is justified NOT primarily by standalone risk/reward, but by:
1. The HEDGING value against consumer discretionary longs (DOM.L, MONY.L, LULU)
2. The portfolio-level diversification benefit (first short, bidirectional)
3. The EXPECTED VALUE being positive (+18-20% expected return)
4. The tail scenario being very attractive (+45-68% if structural remedy)

**Verdict: PASS.** Asymmetric risk is managed through sizing (1%), stop loss ($195), and no leverage. The position-level ratio is mildly unfavorable but portfolio-level impact is trivial. Hedging value provides additional justification.

---

### Gate 13: BIDIRECTIONAL PORTFOLIO FIT (P12) -- **PASS**

```
[X] Adding this short improves net exposure: 39.3% -> 38.3% (mild, appropriate)
[X] This is the FIRST short position -> establishes bidirectional capability (P12)
[X] Hedges consumer discretionary longs:
    - DOM.L (UK pizza, consumer discretionary)
    - MONY.L (UK comparison shopping, consumer)
    - LULU (US athleisure, consumer discretionary)
    All three would suffer if consumer sentiment weakens; LYV short would profit
[X] No conflict with existing positions (no long entertainment/ticketing exposure)
[X] Correlation with existing longs: LOW (different sector, different business model)
```

**Does adding this short improve the portfolio total?**
- YES on net exposure (reduces from 39.3% to 38.3%, consistent with cautious stance)
- YES on diversification (adds short side, previously absent)
- YES on hedging (consumer discretionary hedge)
- NEUTRAL on cash (no cash consumed)
- MARGINAL on alpha generation (1% sizing limits return contribution to 0.18-0.20% of portfolio max)

**Verdict: PASS.** The short position improves the portfolio on multiple dimensions.

---

## SUMMARY OF ALL 13 GATES

| Gate | Verdict | Key Issue |
|------|---------|-----------|
| 0. Sector View | **CONDITIONAL PASS** | No sector view file. Must create before execution. |
| 1. Thesis Quality | **PASS** | Thorough, multi-method, primary data used |
| 2. Quality Score | **PASS** | QS 41 vs 114x P/E = wide overvaluation gap |
| 3. Valuation | **PASS** | All methods confirm overvaluation. FV $85 (S3) |
| 4. Catalyst | **PASS** | March 2 DOJ trial. Dated. Cover protocol defined |
| 5. Kill Conditions | **PASS** | 4 KCs, specific, monitorable, actionable |
| 6. Sizing | **PASS** | 1% = conservative. Half of half-position precedent |
| 7. Risk Identification | **PASS** | Comprehensive. Google precedent acknowledged |
| 8. DA Survival | **PASS** | Bull case 5.5/10. Thesis survived with adjustments |
| 9. Portfolio Fit | **PASS** | Hedging, bidirectional, low correlation, no cash used |
| 10. Sector View | **CONDITIONAL PASS** | Same as Gate 0 |
| 11. Catalyst Anchor (P10) | **PASS** | March 2 trial. Carry acceptable |
| 12. Asymmetry (P11) | **PASS** | 1% sizing + stop $195 + no leverage = capped risk |
| 13. Bidirectional (P12) | **PASS** | First short. Improves portfolio on multiple dimensions |

**Gates Passed:** 11 clean PASS + 2 CONDITIONAL PASS (both on same issue: sector view)

---

## VERDICT: **APPROVED_CONDITIONAL**

### Conditions (ALL must be met before execution):

1. **HARD: Create sector view** `world/sectors/live-entertainment.md` before the human opens the position in eToro. This can be a condensed sector view given the embedded analysis in S1, but it MUST exist as a standalone file.

2. **HARD: Entry AFTER Q4 earnings release** (per S3 recommendation). Q4 earnings were expected around Feb 19. Verify earnings are released and assess any material changes before entry. If Q4 shows organic growth >10% or deferred revenue reversing, RE-EVALUATE before entering.

3. **SOFT: Entry BEFORE March 2 trial start.** Ideal entry window: Feb 20-28 (post-earnings, pre-trial). If the stock gaps significantly on earnings, re-assess entry price vs $195 stop loss.

### Exact Parameters for Standing Order:

```yaml
- ticker: LYV
  action: SHORT
  trigger: "Post-Q4 earnings confirmed, $145-160 range"
  size_eur: 100
  fair_value_short: "$85"
  catalyst: "DOJ antitrust trial March 2, 2026 + 40 state AGs"
  catalyst_date: 2026-03-02
  carry_cost_note: "~7-8% annual on eToro CFD (~EUR 0.63/month)"
  max_duration: "6 months initially; re-evaluate quarterly"
  stop_loss: "$195 (max loss EUR ~24 = 0.24% of portfolio)"
  instrument: "CFD short, x1 leverage, no margin"
  kill_conditions:
    - "KC#1: DOJ + all states settle simultaneously -> COVER IMMEDIATELY"
    - "KC#2: Stock > $195 -> COVER (stop loss)"
    - "KC#3: Organic revenue growth >10% 2 consecutive quarters -> RE-EVALUATE"
    - "KC#4: Carry cost > 8% of position without catalyst -> COVER within 30 days"
  pre_execution_conditions:
    - "Sector view world/sectors/live-entertainment.md MUST exist"
    - "Q4 2025 earnings confirmed and reviewed"
  notes: "S4 APPROVED CONDITIONAL. First-ever short position. 1% sizing (half of half-position precedent). Binary legal catalyst. Google antitrust precedent is main counter-risk."
  last_analysis_date: 2026-02-19
  expiry: 2026-09-01
```

### Recommendation to Human:

```
RECOMMENDATION: SHORT EUR 100 of LYV (~0.7 shares CFD at $156.88)

Quality Score: 41/100 (Tier C) -- priced at 114x P/E (Tier A+ pricing)
Fair Value (short thesis): $85 (S3 revised from S1's $74)
Expected Return: +18-20% (probability-weighted)
Sizing: 1% of portfolio (EUR 100) -- half of half-position precedent
Stop Loss: $195 (max loss EUR 24 = 0.24% of portfolio)
Catalyst: DOJ antitrust trial March 2, 2026
Risk principal: DOJ settlement removes overhang; Google precedent (behavioral > structural)
Kill condition: COVER if DOJ + all states settle simultaneously

CONDITIONS BEFORE EXECUTION:
1. Sector view must be created
2. Q4 earnings must be confirmed and reviewed
3. Entry window: Feb 20-28 (post-earnings, pre-trial)

Confirm when ready to execute in eToro?
```

---

## META-REFLECTION

### Dudas sobre esta decision

1. **The position-level risk/reward ratio is slightly unfavorable (0.74-0.82:1).** This is unusual -- typically we require favorable ratios. The justification rests on portfolio-level impact (0.24% max loss) and hedging value, not standalone attractiveness. If this were a 4% position, I would REJECT on risk/reward grounds.

2. **The Google antitrust precedent is the single strongest argument against this short.** The S3 resolution reduced structural remedy probability from 20% to 10%, which is reasonable, but the broader point -- that US courts in the modern era do not order structural breakups of platform monopolies -- is a genuine epistemic concern. If the market is RIGHT that behavioral remedies are the only realistic outcome, the thesis weakens considerably (though it doesn't collapse, because even behavioral remedies create uncertainty that suppresses the multiple temporarily).

3. **Q4 earnings timing creates execution risk.** If LYV reports strong Q4 with aggressive 2026 guidance, the stock could gap to $165-170 before we enter. At that price, the stop at $195 provides only 15% room, which is tighter. The entry window is narrow.

4. **This is our FIRST short ever.** There is inherent execution uncertainty -- CFD mechanics on eToro, carry cost tracking, monitoring protocols. The 1% sizing limits the learning cost if something goes wrong mechanically.

### Debilidades del analisis recibido

1. **S1 did not access the 10-K directly.** AOI figures come from press releases and news reports (Nivel 2). For a short thesis where the profit engine (Ticketmaster 52% of AOI) is the central argument, this should ideally be verified against primary filings.

2. **S1's reverse DCF uses COVID-distorted FCF CAGR.** The tool flagged -13.5% FCF CAGR, but this starts from a 2021 base year when FCF was inflated by deferred revenue timing effects. A more representative base would be 2023-2024, showing modest FCF growth.

3. **S2's ARPU anomaly was noted but not fully resolved.** Per-fan ARPU declined in Q2 2025 ($134.69 vs $151.16). This contradicts both the bull "pricing power" narrative and suggests growth quality is lower than both sides assume. The S3 noted it but did not quantify the impact on valuation.

4. **No live-entertainment sector view means we lack competitive landscape context** -- specifically, how strong are AXS, SeatGeek, DICE in practice? Is there actually a viable alternative to Ticketmaster if behavioral remedies open the market? This is critical for assessing post-remedy value.

### Sugerencias de mejora

1. **Create a short-specific precedent section in decisions_log.yaml** after this decision. Future short decisions need precedents to reference.

2. **The insider_tracker tool should distinguish between option exercises (monetization) and open-market purchases (conviction).** S1 flagged this as a limitation. Both are reported the same way.

3. **Consider a "binary event sizing" principle** that formalizes the half-position pattern. We now have MMC (long, half due to Greensill) and LYV (short, 1% due to DOJ trial). A formal principle would prevent inconsistency.

### Preguntas para Orchestrator

1. **When should the sector view be created -- this session or next?** The human may want to execute the short quickly given the narrow entry window (Feb 20-28). If we delay sector view creation to next session, we block execution.

2. **Should we track LYV Q4 earnings results in the earnings framework before approving final entry?** S2 flagged that Q4 earnings (around Feb 19) could materially change the thesis. If Q4 shows organic growth re-acceleration, the thesis weakens.

3. **For the standing_orders.yaml entry: should we add this to `short_orders` (currently empty)?** This would be the first entry in that section, establishing the format for future short orders.
